GHK-Cu and BPC-157 are two of the most widely studied peptides in the regenerative biology and tissue research literature. Though sometimes grouped together in discussions of “repair-related” research compounds, they are structurally distinct, operate through different molecular mechanisms, and have been investigated in entirely different research contexts. This comparison outlines the key mechanistic and research differences between the two compounds — for educational and research reference only.

What is GHK-Cu?

GHK-Cu (copper peptide glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide first isolated from human plasma in the early 1970s. The “Cu” designation refers to its copper(II) binding property — the tripeptide forms a stable complex with copper ions, which appears to be central to its documented biological activities in research models.

GHK-Cu belongs to a class of copper-binding peptides studied for their effects on gene expression regulation. Microarray studies published by Loren Pickart and colleagues have reported that GHK-Cu modulates the expression of a large number of human genes, with particular effects observed on pathways related to collagen synthesis, antioxidant response, and tissue remodelling. It has been characterized as a naturally occurring chemoattractant in wound healing research models, where it appears to influence the migration and activity of cells involved in extracellular matrix maintenance.

See our dedicated guide: What is GHK-Cu?

What is BPC-157?

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a 15-amino-acid sequence derived from a partial sequence of human gastric juice protein BPC. Unlike GHK-Cu, which is a naturally occurring endogenous peptide, BPC-157 is a synthetic research compound designed for stability in physiological conditions.

BPC-157 has been extensively studied in rodent models, primarily in the context of gastrointestinal biology, angiogenesis, and tendon-related research. Its research profile is notable for the breadth of organ systems and biological processes that have been studied in preclinical models — though translational evidence in humans remains limited and the compound has no current regulatory approval for therapeutic use. A key area of investigation has been its apparent interaction with growth factor signalling cascades, particularly the VEGF and NO (nitric oxide) pathways in vascular research models.

See our dedicated guide: What is BPC-157?

Mechanism Differences

Feature	GHK-Cu	BPC-157
Structure	Tripeptide + copper(II) complex	Synthetic pentadecapeptide (15 aa)
Origin	Naturally occurring in human plasma	Synthetic, derived from gastric BPC
Primary mechanism	Copper-mediated gene expression modulation; collagen biology; antioxidant pathway regulation	Growth factor signalling (VEGF, EGF, bFGF); NO pathway; angiogenesis in preclinical models
Key research areas	Skin biology, ECM remodelling, gene expression, wound healing models	GI research, tendon models, angiogenesis, vascular biology
Human research status	Limited; primarily preclinical and in vitro	Very limited; primarily preclinical (rodent models)
Stability	Sensitive to oxidation; copper coordination important	Reported as relatively stable in physiological conditions in preclinical research

Research Areas

GHK-Cu Research Context

The bulk of GHK-Cu research has focused on dermal biology, wound healing models, and gene expression analysis. Pickart’s research group published extensively on GHK-Cu’s ability to upregulate collagen, glycosaminoglycan, and decorin production in fibroblast cultures. Separately, researchers have investigated its role in attracting immune cells and fibroblasts to wound sites in animal models. More recent work has explored its broader genomic effects, with some researchers reporting that GHK-Cu modulates gene expression in patterns associated with anti-inflammatory and antioxidant responses at the cellular level.

Research has also been conducted on GHK-Cu in the context of neuronal and bronchial epithelial models, suggesting a broader range of potential biological activity than early dermal-focused work implied — though the significance of these findings for any specific application requires further study.

BPC-157 Research Context

BPC-157 research has been conducted predominantly by research groups in Croatia, with a large volume of rodent model studies examining its effects across a range of tissue types. The compound’s interaction with the nitric oxide system has been a focus of mechanistic investigation, as researchers have explored whether NO pathway modulation underlies some of its observed preclinical effects on vascular biology and tissue healing models. Studies examining its effects in GI tissue models have characterized its apparent cytoprotective properties at the cellular level.

It is important to note that BPC-157 has not been approved for human therapeutic use by any major regulatory authority. Most of the published research is in rodent models, and translating these findings to human biology requires careful consideration of bioavailability, pharmacokinetics, and species-specific differences.

Key Differences for Researchers

Researchers selecting between these compounds for laboratory work should consider the mechanistic focus of their research:

• If the research involves collagen biology, ECM remodelling, or copper-mediated gene expression: GHK-Cu’s well-characterized copper tripeptide chemistry makes it the more targeted choice for those specific mechanistic questions.
• If the research involves growth factor signalling pathways, angiogenesis models, or GI tissue biology: BPC-157’s broader preclinical dataset across these areas makes it a more relevant research reference compound.
• Both compounds are frequently studied in the context of wound healing biology at the cellular level, though via distinct molecular entry points.

For quality and purity standards applicable to research use of both compounds, see our Quality & Purity page.

TrueCanPeptides supplies GHK-Cu 50mg and BPC-157 10mg as research compounds for laboratory use.

---

Research Use Disclaimer: This content is provided for educational and informational purposes relating to scientific research only. The compounds discussed on this page are sold exclusively for laboratory research purposes and are not intended for human consumption, self-administration, or therapeutic use. They are not approved by Health Canada or any other regulatory authority for use in humans unless specifically stated. Nothing on this page constitutes medical advice, a treatment recommendation, or encouragement of self-medication. Consult a qualified healthcare professional for any health-related concerns.

See also: BPC-157 vs TB-500

Structural Comparison

GHK-Cu Structure

GHK-Cu (copper peptide GHK-Cu) is a naturally occurring tripeptide — glycine-histidine-lysine (Gly-His-Lys) — complexed with a copper(II) ion. It was first isolated from human plasma by Loren Pickart in 1973. The copper coordination occurs primarily through the imidazole nitrogen of histidine and the terminal amine of glycine, forming a stable square planar complex.

• Sequence: Gly-His-Lys (3 amino acids)
• Molecular weight: ~340 Da (peptide); ~403 Da with copper
• Natural occurrence: Found in human plasma, saliva, and urine
• Copper coordination: Cu²⁺ complexed via histidine imidazole and glycine amine

BPC-157 Structure

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino acid sequence (GEPPPGKPADDAGLV) derived from a segment of the naturally occurring Body Protection Compound found in human gastric juice. Unlike GHK-Cu, BPC-157 does not naturally occur in this form — it is a research-derived fragment. It has no known endogenous receptor and its mechanism is studied through indirect pathway modulation.

• Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids)
• Molecular weight: ~1,419 Da
• Origin: Derived from human gastric juice protein BPC
• Metal coordination: None

Mechanism of Action: Key Differences

GHK-Cu Mechanisms

GHK-Cu’s research-documented mechanisms include:

• Copper delivery: Acts as a copper chaperone, delivering Cu²⁺ to copper-dependent enzymes including lysyl oxidase (collagen/elastin crosslinking) and superoxide dismutase (antioxidant defence)
• Gene expression modulation: Research has shown GHK-Cu modulates expression of ~4,000 human genes, including upregulation of tissue repair and anti-inflammatory genes and downregulation of inflammatory and cancer-promoting genes (Pickart/Margolina, 2018)
• TGF-β pathway: Investigated for its effects on transforming growth factor-beta signalling, relevant to fibrosis and tissue remodelling research
• Antioxidant activity: Cu²⁺ in the GHK-Cu complex contributes to superoxide dismutase-like activity in some research models

BPC-157 Mechanisms

BPC-157’s proposed mechanisms are broader and less directly characterized:

• Nitric oxide system: Proposed modulation of nitric oxide (NO) production, which may influence angiogenesis and vascular biology in preclinical models
• Growth factor upregulation: Research in animal models has associated BPC-157 with upregulation of growth factors including EGF and VEGF at injury sites
• Cytoskeletal signalling: Some research suggests interactions with FAK (focal adhesion kinase) and paxillin signalling pathways involved in cell migration and wound healing biology
• Gut-brain axis: Given its gastric origin, BPC-157 has been studied in models of gut motility, mucosal integrity, and the enteric nervous system

Research Literature: Where They Differ

The research literatures for these two compounds are substantively different in character:

• GHK-Cu: Has a well-established basic science literature beginning in the 1970s. Multiple peer-reviewed papers from Western research institutions. Strong mechanistic work on gene expression, copper biology, and wound healing. Has been incorporated into topical cosmetic formulations, creating a substantial applied research base.
• BPC-157: Research is primarily from Croatian research groups (Sikiric et al., University of Zagreb). Large body of animal model research but limited independent replication. No approved pharmaceutical applications. Characterization of its mechanism is still incomplete.

Side-by-Side Comparison Table

Property	GHK-Cu	BPC-157
Type	Tripeptide + copper complex	Synthetic pentadecapeptide
Size	3 amino acids, ~403 Da	15 amino acids, ~1,419 Da
Natural occurrence	Yes — human plasma	No — research-derived fragment
Primary mechanism	Copper delivery, gene modulation	NO system, growth factor modulation
Research origin	Western (Pickart, 1973)	Croatian (Sikiric et al.)
Replication breadth	Wide — multiple independent groups	Narrow — primarily one research group
Research context	Skin biology, wound healing, fibrosis	GI biology, tissue injury models
Metal coordination	Yes — Cu²⁺	No

Storage and Handling Notes

• GHK-Cu: Store at −20°C, protected from light. The copper complex is stable when lyophilized but can oxidize in solution over time. Reconstitute in sterile water; use promptly or aliquot and refreeze.
• BPC-157: Store at −20°C in sealed vial. Lyophilized form is stable. Reconstitute in sterile water or bacteriostatic water. Avoid prolonged exposure to room temperature post-reconstitution.

Both compounds are supplied by TrueCanPeptides for qualified in vitro laboratory research purposes only. Not intended for human or animal administration. Not evaluated or approved by Health Canada.

Available from TrueCanPeptides: GHK-Cu 50mg | BPC-157 10mg | TB-500 10mg

Related reading: Semaglutide vs Tirzepatide vs Retatrutide | What Are Peptides? | Quality Standards